In conclusion, the effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumour expression after initial therapy, relative to that of standard chemotherapy, was evaluated in patients with HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.